An IPO So Nice REGENXBIO Will Try It Twice
This article was originally published in Scrip
REGENXBIO Inc. is hoping to build on the success of its IPO – and investor enthusiasm for gene therapy in general – by taking its liver disease-focused spinout, Dimension Therapeutics Inc., public as well.
You may also be interested in...
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.